Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis

BACKGROUND: Apatinib is a tyrosine kinase inhibitor (TKI) that selectively inhibits the vascular endothelial growth factor receptor-2. A weighted pooled analysis was performed to evaluate the clinical outcome, efficacy, and toxicity of apatinib in patients with advanced nonsmall cell lung cancer (NS...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Jie-Tao, Sun, Jing, Sun, Li, Zhang, Shu-Ling, Huang, Le-Tian, Han, Cheng-Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392903/
https://www.ncbi.nlm.nih.gov/pubmed/30170427
http://dx.doi.org/10.1097/MD.0000000000012083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392903/
https://www.ncbi.nlm.nih.gov/pubmed/30170427
http://dx.doi.org/10.1097/MD.0000000000012083

Ejemplares similares